BiotechTube

mRNA-1018 for H5N8

Phase 2Completed
1 views this week 0 watching
0
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Influenza

Conditions

Influenza

Trial Timeline

Jul 10, 2023 → Jul 16, 2024

NCT ID
NCT05972174

About mRNA-1018 for H5N8

mRNA-1018 for H5N8 is a phase 2 stage product being developed by Moderna for Influenza. The current trial status is completed. This product is registered under clinical trial identifier NCT05972174. Target conditions include Influenza.

What happened to similar drugs?

20 of 20 similar drugs in Influenza were approved

Approved (20) Terminated (1) Active (0)
✅Monovalent Influenza VaccineAstraZenecaApproved
✅Monovalent Influenza VaccineAstraZenecaApproved
✅Trivalent Influenza VaccineAstraZenecaApproved
✅Trivalent Influenza VaccineAstraZenecaApproved
✅FluMist trivalent (2015-2016) + FluMist Quadrivalent (2015-2016) + FluMist Quadrivalent (2017-2018)AstraZenecaApproved
✅Trivalent Influenza Virus VaccineAstraZenecaApproved
✅Vaxelis + PedvaxHIBMerckApproved

Clinical Trials (1)

NCT IDPhaseStatus
NCT05972174Phase 2Completed

Competing Products

20 competing products in Influenza

See all competitors
ProductCompanyStageHype Score
mRNA-1010ModernaPhase 1
0
mRNA-1273ModernaPhase 1
0
mRNA-1010ModernaPhase 2
0
mRNA-1083 Composition 1 Dose A Lot AModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
mRNA-1011.1ModernaPhase 2
0
mRNA-1083.1ModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
mRNA-1083ModernaPhase 3
0
mRNA-1073ModernaPhase 2
0
VAL-506440ModernaPhase 1
0
mRNA-1083ModernaPhase 3
0
mRNA-1083ModernaPhase 2
0
mRNA-1010ModernaPhase 3
0
VAL-339851ModernaPhase 1
0
mRNA-1018-H5ModernaPhase 3
0
mRNA-1653ModernaPhase 1
0
mRNA-1030ModernaPhase 2
0
mRNA-1653ModernaPhase 1
0
mRNA-1010ModernaPhase 2
0